Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02552121 · ClinicalTrials.gov registry record · Phase 1
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02552121 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 33 participants.
The verdict
NCT02552121, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
Interventions
- DRUG Tisotumab vedotin (HuMax-TF-ADC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2017-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02552121
The ClinicalTrials.gov registry entry for NCT02552121 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tisotumab vedotin (HuMax-TF-ADC) is the first listed.
NCT02552121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02552121 about?
NCT02552121 is a clinical study titled "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors". The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
What is the current status of trial NCT02552121?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-11-30. Estimated completion is 2017-12-13.
What interventions are being tested in trial NCT02552121?
The interventions under investigation include: Tisotumab vedotin (HuMax-TF-ADC) (DRUG).
Who is sponsoring clinical trial NCT02552121?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.